

CLEARBRIDGE HEALTH LIMITED
(Company Number: 201001436C)
(Incorporated in the Republic of Singapore)

RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 28 JUNE 2023

The board of directors (“**Board**” or “**Directors**”) of Clearbridge Health Limited (the “**Company**”) wishes to announce that all the proposed resolutions relating to the matters as set out in the notice of annual general meeting (“**AGM**”) dated 13 June 2023, were duly passed by shareholders of the Company by way of poll at the AGM held by electronic means on 28 June 2023.

Pursuant to Rule 704(15) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”)(“**Catalist Rules**”), the following information relating to the AGM are disclosed:

Poll results

Resolution number and details		Total no. of shares represented by votes for and against the relevant resolution	For		Against	
			No. of shares	As a percentage of total no. of votes for and against the resolution (%)	No. of shares	As a percentage of total no. of votes for and against the resolution (%)
Ordinary Business						
1.	To receive and adopt the audited financial statements of the Company for the financial year ended 31 December 2022, the directors’ statement and the auditor’s report thereon	176,306,426	171,674,426	97.37	4,632,000	2.63
2.	To approve the payment of directors’ fees of S\$165,000 for the financial year ending 31 December 2023, payable quarterly in arrears	100,907,326	96,275,326	95.41	4,632,000	4.59
3.	To re-elect Mr Mark Benedict Ryan as a Director of the Company	176,306,426	171,654,426	97.36	4,652,000	2.64
4.	To appoint Messrs CLA Global TS Public Accounting Corporation as auditors of the Company in place of the retiring auditors, Messrs Ernst & Young LLP	176,306,426	171,654,426	97.36	4,652,000	2.64
Special Business						
5.	To authorise the Directors to allot and issue shares in the capital of the Company	176,306,426	171,674,426	97.37	4,632,000	2.63
6.	To authorise the Directors to grant awards and to allot and issue shares pursuant to the Clearbridge Health Performance Share Plan (“ PSP ”)	89,744,122	85,014,122	94.73	4,730,000	5.27

Mr Mark Benedict Ryan, having been re-elected as a Director, remains as an independent director, chairman of the audit committee, and a member of the remuneration committee of the Company. He is considered to be independent for the purpose of Rule 704(7) of the Catalist Rules.

Abstention from Voting

Details of parties who are required to abstain/voluntarily abstain from voting on the following resolutions:

Resolution no.	Name	No. of shares
Resolution 2 - To approve the payment of directors' fees of S\$165,000 for the financial year ending 31 December 2023, payable quarterly in arrears	Chen Johnson Yee Pinh Jeremy Mark Benedict Ryan	77,055,100 27,482,175 2,097,600
Resolution 3 - To re-elect Mr Mark Benedict Ryan as a Director of the Company	Mark Benedict Ryan	2,097,600
Resolution 6 - To authorise the Directors to grant awards and to allot and issue shares pursuant to the PSP	Shareholders who are eligible to participate in the PSP	130,792,589

Appointment of Scrutineer

B.A.C.S Private Limited was appointed as scrutineer for the polling process at the AGM.

By Order of the Board

Yee Pinh Jeremy
Executive Director and Chief Executive Officer
28 June 2023

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Catalist Rules.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone:+65 6533 9898.